The #MAVORIC trial led by Dr. Francine Foss demonstrated greater efficacy with mogamulizumab vs. vorinostat in relapsed/refractory patients with #CTCL, including those with more advanced disease.
pubmed.ncbi.nlm.nih.gov/39894454/
@yale-hematology.bsky.social @yaleschoolofmed.bsky.social
1
1
0
0